Allergan has acquired worldwide rights to TARIS Biomedical’s lead program, LiRIS, currently in Phase II development for the treatment of interstitial cystitis / bladder pain syndrome (IC/BPS), for $67.5 million in cash. Allergan will also pay as much as $295 million in development milestones, and as much as $225 million in commercial milestones.   TARIS previously spun out certain assets, including pipeline programs and intellectual property related to TARIS’ platform technology, to a new compan...